Cargando…
The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease
Inflammatory bowel disease (IBD), a chronic gut immune dysregulation and dysbiosis condition is rapidly increasing in global incidence. Regardless, there is a lack of ideal diagnostic markers, while conventional treatment provides scarce desired results, thus, the exploration for better options. Cha...
Autores principales: | Xu, Xinwei, Ocansey, Dickson Kofi Wiredu, Hang, Sanhua, Wang, Bo, Amoah, Samuel, Yi, Chengxue, Zhang, Xu, Liu, Lianqin, Mao, Fei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215062/ https://www.ncbi.nlm.nih.gov/pubmed/35729658 http://dx.doi.org/10.1186/s13099-022-00499-9 |
Ejemplares similares
-
The diagnostic and prognostic potential of gut bacteria in inflammatory bowel disease
por: Wiredu Ocansey, Dickson Kofi, et al.
Publicado: (2023) -
Human umbilical cord mesenchymal stem cells derived exosome shuttling mir-129-5p attenuates inflammatory bowel disease by inhibiting ferroptosis
por: Wei, Zhiping, et al.
Publicado: (2023) -
Cellular and molecular mediators of lymphangiogenesis in inflammatory bowel disease
por: Ocansey, Dickson Kofi Wiredu, et al.
Publicado: (2021) -
Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer
por: Zhou, Mengjiao, et al.
Publicado: (2022) -
Mesenchymal stem cell–gut microbiota interaction in the repair of inflammatory bowel disease: an enhanced therapeutic effect
por: Ocansey, Dickson Kofi Wiredu, et al.
Publicado: (2019)